Compounds for the treatment of metabolic diseases (diabetes)；Lung, heart, eye diseases (diabetic retinopathy, glaucoma)Ignition - characteristic 1: a formulated compound (1),wherein: R¹ is haloalkyl, halophenyl, alkoxyphenyl, alkyl-1,2,5-oxadiazolyl, haloalkylphenyl, alkylsulfonylphenyl, halo-pyridinyl or alkyltetrazolyl； R² is cycloalkyl, isopropyl, alkenyl, piperidinyl, alkylamino, azetidinyl, pyrrolidinyl, cycloalkylamino, alquiloxetanilamino, morpholinyl, (cycloalkyl) (alkyl) amino, haloalkyloxy, alkoxy, cycloalkylalkoxy, cycloalkyloxy, oxetanyloxy, alquiloxetanilalquiloxi, alkynyloxy, alkoxy-alkoxy, hydroxyalkyloxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfonyl, hydroxyalkylsulfanyl, hydroxy-alkylsulfonyl or alkoxyalkylsulfonyl； R³ and R⁴ are independently chosen from hydrogen, halogen, hydroxyl,1. Asphalt and asphalt, provided that R 3 and r830808 are not hydrogen at the same time； n is 1 or 2； or 1 or 2； or 1 or 2； or salt or ester acceptable to the agent； provided that 3 - [3 - (4-methoxi-bencil) - 5 - (2,2-trifluoro-etoxi) - 3 - [1,2,3] triazole [4,5-d] pirimidin-7-pirin] - Pirin - Tri is not included.Compuestos útiles en el tratamiento de enfermedades del SNC, metabólicas (diabetes), pulmonares, cardiacas, trastornos oculares (retinopatía diabética, glaucoma), inflamación. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R¹ es haloalquilo, halofenilo, alcoxifenilo, alquil-1,2,5-oxadiazolilo, haloalquilfenilo, alquilsulfonilfenilo, halo-piridinilo o alquiltetrazolilo； R² es cicloalquilo, isopropilo, alquenilo, piperidinilo, alquilamino, azetidinilo, pirrolidinilo, cicloalquilamino, alquiloxetanilamino, morfolinilo, (cicloalquil)(alquil)amino, haloalquiloxi, alcoxi, cicloalquilalcoxi, cicloalquiloxi, oxetaniloxi, alquiloxetanilalquiloxi, alquiniloxi, alcoxi-alcoxi, hidroxialquiloxi, alquilsulfanilo, haloalquil-sulfanilo, alquilsulfonilo, hidroxialquilsulfanilo, hidroxi-alquilsulfonilo o alcoxialquilsulfonilo； R³ y R⁴ se eligen con independencia
